Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN  
766.39
+5.15 (+0.68%)
7:56:04 PM EDT: $766.10 -0.29 (-0.04%)
Products, Strategic Combinations

Cytomx And Regeneron Announce Strategic Research Collaboration In The Field Of Conditional Bispecific Therapeutics For The Treatment Of Cancer

Published: 11/17/2022 12:47 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Cytomx and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer.
Regeneron - Cytomx to Receive $30 Million Upfront Payment With Potential for Up to $2 Billion in Research, Development, Regulatory and Sales-based Milestones.
Regeneron Pharmaceuticals Inc - Cytomx is Also Eligible to Receive Tiered Global Net Sales Royalties.